Updated Evidence: PSA Screening Tied to Lower Prostate Cancer Death Risk

Introduction

A comprehensive new review from the respected Cochrane Collaboration suggests that prostate-specific antigen (PSA) blood testing may reduce the number of deaths caused by prostate cancer. Published in March 2025, this analysis marks a notable shift in the medical community's understanding of the screening's benefits and could influence future guidelines.

What the Cochrane Review Found

The review, led by Dr. Juan Franco of Heinrich Heine University Düsseldorf in Germany, pooled data from six large trials conducted in Europe and North America, encompassing over 800,000 participants. After evaluating the evidence, the researchers concluded with moderate certainty that PSA screening leads to a reduction in deaths specifically due to prostate cancer.

The Numbers Behind the Benefit

While the benefit is statistically significant, it remains modest in absolute terms. For every 1,000 men screened, approximately two fewer deaths from prostate cancer occur over a follow-up period. This translates to a number needed to screen of about 500 to prevent one prostate cancer death.

Understanding PSA Screening

PSA is a protein produced by the prostate gland; elevated levels in the blood can indicate the presence of prostate cancer, though they may also result from benign conditions such as enlargement or infection. The test has long been a subject of debate because it can lead to overdiagnosis and overtreatment of slow-growing tumors that would never cause harm.

The Controversy Around PSA Testing

In the past, major health organizations have issued conflicting recommendations. The U.S. Preventive Services Task Force (USPSTF), for example, initially recommended against routine PSA screening in 2012, then revised its stance in 2018 to suggest that men aged 55 to 69 make an individual decision after discussing risks and benefits with their doctor. The new Cochrane review strengthens the case for screening by providing more precise mortality data.

Details of the Analyzed Trials

The six trials included in the Cochrane analysis were conducted across different settings:

• European Randomized Study of Screening for Prostate Cancer (ERSPC) – the largest study, showing a significant reduction in prostate cancer mortality.
• Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial from the United States, which had high rates of contamination in the control group.
• Four smaller trials from Sweden, Finland, and Canada, contributing additional data.

By combining these studies, the Cochrane team achieved greater statistical power to detect a mortality benefit, even when individual trials had conflicting results.

Implications for Clinical Practice

Dr. Franco emphasized that the findings support shared decision-making. “For men who are considering screening, this review provides reliable data that a small but real reduction in prostate cancer death can be expected,” he said during a press conference. He noted that the harms of screening, such as false positives and unnecessary biopsies, must still be weighed.

Who Should Consider Screening?

Current guidelines suggest that men at higher risk—such as those with a family history of prostate cancer or of African descent—may benefit more from screening. The Cochrane review supports this personalized approach. Learn more about PSA testing basics.

What Comes Next

The review is likely to prompt updates to national screening recommendations. Some countries, such as those in Scandinavia, have already introduced organized PSA screening programs. The new evidence may encourage broader implementation, especially if combined with strategies to reduce overdiagnosis, such as using MRI scans before biopsy and adopting active surveillance for low-risk cancers.

Conclusion

The Cochrane review provides compelling, moderate-certainty evidence that PSA screening reduces prostate cancer-specific mortality, albeit with a modest effect size. Men and their clinicians can use this information to have more informed discussions about the potential benefits and harms of screening. As research continues, refining who gets screened and how abnormal results are managed will remain crucial.

For a deeper dive into the methodology, see the discussion on trial details.